Growth & profitability
- Revenue has grown 20.4% per year over the past 5 years.
- Operating margin has expanded, at -6.9% in the latest year.
Financial health
- Operating income covered interest expense -1.1× in the latest year.
SKIN Financials SkinHealth Systems Inc.
7 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $301M | -$10M | 65.3% | -6.9% | $37M | — | $233M |
| 2024 | $334M | -$29M | 54.5% | -20.3% | $15M | $552M | $370M |
| 2023 | $398M | -$100M | 39.0% | -32.9% | $18M | — | $523M |
| 2022 | $366M | $44M | 68.0% | -7.1% | -$117M | — | $568M |
| 2021 | $260M | $379M | 68.6% | -15.4% | -$40M | — | $902M |
| 2020 | $119M | -$29M | 56.4% | -14.4% | -$16M | — | $9M |
| 2019 | $167M | -$2M | 63.9% | 8.1% | -$7M | — | $7M |
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $65M | -$7M | 68.5% | -2.8% | -$6M | — | $204M |
| Dec '25 | $82M | -$8M | 64.4% | 0.2% | $15M | — | $233M |
| Sep '25 | $71M | -$11M | 64.6% | -8.8% | $10M | $363M | $219M |
| Jun '25 | $78M | $20M | 62.8% | -3.5% | $10M | $363M | $212M |
| Mar '25 | $70M | -$10M | 69.8% | -17.3% | $3M | — | $373M |
| Dec '24 | $83M | -$10M | 62.7% | -8.6% | $16M | $552M | $370M |
| Sep '24 | $79M | -$18M | 51.6% | -27.3% | $10M | — | $359M |
| Jun '24 | $91M | $202000 | 45.2% | -24.4% | $6M | — | $350M |
| Mar '24 | $81M | -$679000 | 59.4% | -20.9% | -$17M | — | $445M |
| Dec '23 | $97M | -$9M | 47.2% | -19.0% | -$5M | — | $523M |
| Sep '23 | $97M | -$74M | -12.9% | -84.3% | $18M | — | $559M |
| Jun '23 | $117M | $3M | 57.8% | -11.2% | $21M | — | $550M |
| Mar '23 | $86M | -$20M | 62.7% | -20.1% | -$15M | — | $532M |
| Dec '22 | $98M | $7M | 67.8% | -2.5% | -$6M | — | $568M |
| Sep '22 | $89M | -$81000 | 69.1% | -4.9% | -$36M | — | $684M |
| Jun '22 | $104M | $6M | 67.6% | -4.9% | -$34M | — | $821M |
| Mar '22 | $75M | $31M | 67.5% | -18.6% | -$42M | — | $859M |
| Dec '21 | $78M | -$17M | 72.9% | -9.3% | -$3M | — | $902M |
| Sep '21 | $68M | -$215M | 67.6% | -8.0% | $148000 | — | $719M |
| Jun '21 | $67M | -$139M | 71.0% | -39.6% | -$37M | — | $101M |
Valuation over time
How the market has priced SKIN against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-earnings ratio has fallen from 37.0× (Mar '23) to 9.1× (Dec '23).
- The price-to-sales ratio has fallen from 4.5× (Mar '23) to 0.3× (Jun '26).
P/E
P/S
Frequently asked questions
Is SKIN growing its revenue and profit?
Over the past 5 years, SkinHealth Systems Inc.'s revenue has grown 20.4% per year. These are computed facts, not advice.
How much debt does SKIN have?
As of FY2025, SkinHealth Systems Inc. reported — of total debt against $233M of cash; operating income covered interest expense -1.1×.
What is SKIN's profit margin?
In FY2025, gross margin was 65.3%, operating margin -6.9%, and net margin -3.2%.
What is SKIN's P/E ratio?
As of Jun '26, SkinHealth Systems Inc. traded at a price-to-earnings ratio of about 9.1× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.